{"version":"1.0","type":"link","title":"Consecutive real-world treatment experience with a reduced starting dose of lenvatinib (14 mg) plus pembrolizumab for metastatic renal cell carcinoma.","author_name":"Sazuka T 외","author_url":"https://prs-insight.online/author/Sazuka%20T","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/170606","thumbnail_width":1200,"thumbnail_height":630}